Thierry Bernard: Difference between revisions
Content deleted Content added
Created page with "{{Insert top}}{{Insert quote panel | {{Thierry Bernard/random quote}}}} {{section separator}} == Overview == {{Infobox person | name = Thierry Bernard | honorific_prefix = | honorific_suffix = | image = thierry-bernard.jpg | birth_date = October 1964 | birth_place = Lyon, France | citizenship = France | education = Sciences Po; College of Europe; London School of Economics; Centro de Comercio Exterior; Harvard Business School | alma_mater = Sciences Po; College of Euro..." |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
Line 7:
| honorific_suffix =
| image = thierry-bernard.jpg
| birth_date =
| birth_place = Lyon, France
| citizenship = France
Line 24:
| awards = Conseiller du commerce extérieur de la France
| signature =
}}
👤 '''Thierry Bernard''' (born October 1964) is a French business executive who has served as chief executive officer (CEO) of QIAGEN N.V., a multinational molecular diagnostics and life sciences company, since 2019.<ref name="CEORelease">{{cite web |url=https://corporate.qiagen.com/newsroom/press-releases/press-release-details/2020/QIAGEN-names-Thierry-Bernard-as-Chief-Executive-Officer/default.aspx |title=QIAGEN names Thierry Bernard as Chief Executive Officer |publisher=QIAGEN N.V. |accessdate=2025-11-20}}</ref><ref name="CompaniesHouse">{{cite web |url=https://find-and-update.company-information.service.gov.uk/officers/UnNt5A6dIYC99KP59crrn8WE-U8/appointments |title=Thierry Bernard personal appointments |publisher=Companies House |accessdate=2025-11-20}}</ref> Under his leadership QIAGEN expanded its molecular diagnostics portfolio, played a prominent role in global COVID-19 testing and pursued targeted acquisitions such as the 2025 purchase of single-cell sequencing firm Parse Biosciences, while he prepared to step down once a successor is appointed.<ref name="Fierce2025">{{cite web |url=https://www.fiercebiotech.com/medtech/qiagen-ceo-step-down-company-snaps-parse-biosciences-225-million-upfront-deal |title=Qiagen CEO to step down as company snaps up Parse Biosciences |publisher=Fierce Biotech |accessdate=2025-11-20}}</ref><ref name="FocusFirst">{{cite web |url=https://focusfirst.com/2024/03/25/thierry-bernard-ceo-of-qiagen-transforming-beyond-boundaries/ |title=Thierry Bernard, CEO of QIAGEN: Transforming Beyond Boundaries |publisher=FocusFirst |accessdate=2025-11-20}}</ref> Formerly a senior executive at French diagnostics group bioMérieux, he is known for advocating a focused strategy, servant leadership and the treatment of diagnostics as a pillar of public health policy.<ref name="QiagenExec">{{cite web |url=https://www.qiagen.com/us/leadership/executive-committee/thierry-bernard |title=Thierry Bernard |publisher=QIAGEN N.V. |accessdate=2025-11-20}}</ref><ref name="Insights">{{cite web |url=https://s28.q4cdn.com/125951340/files/doc_financials/2022/sr/07/QIAGEN_insights_magazine_2022.pdf |title=QIAGEN Insights magazine 2022 |publisher=QIAGEN N.V. |accessdate=2025-11-20}}</ref>
| |||